Targeted therapy for aggressive breast cancer
Crosslinking-based targeted therapy for triple-negative breast cancer
['FUNDING_R21'] · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · NIH-10828403
This study is testing a new treatment for triple-negative breast cancer that uses tiny particles to deliver medicine directly to cancer cells, helping to stop them from spreading and improving how well the treatment works.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ARIZONA STATE UNIVERSITY-TEMPE CAMPUS (nih funded) |
| Locations | 1 site (TEMPE, UNITED STATES) |
| Trial ID | NIH-10828403 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new targeted therapy for triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer. The approach involves creating specialized nanoparticles that can bind to cancer cells expressing specific receptors (HER1 and/or HER3). These nanoparticles will deliver anticancer drugs directly to the cancer cells, aiming to prevent their spread and improve treatment outcomes. By crosslinking the cancer cells together, the therapy seeks to inhibit their migration and invasion, which are critical factors in cancer metastasis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who have HER1 and/or HER3 receptor expression.
Not a fit: Patients with other subtypes of breast cancer that do not express HER1 or HER3 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple-negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: While targeted therapies for breast cancer have shown promise, this specific crosslinking approach is novel and has not been extensively tested in clinical settings.
Where this research is happening
TEMPE, UNITED STATES
- ARIZONA STATE UNIVERSITY-TEMPE CAMPUS — TEMPE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, SHENGXI — ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
- Study coordinator: CHEN, SHENGXI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug